Molecular heterogeneity of variant Philadelphia translocations in childhood acute lymphoblastic leukaemia. 1994

J A Latham, and N Bown, and G Cain, and P Middleton, and J Kernahan, and K Windebank, and M M Reid
Department of Haematology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.

In acute lymphoblastic leukemia (ALL), it is unclear whether variant Philadelphia (Ph) translocations have the same molecular and clinical implications as the classical translocation. Two children with Ph+ ALL with variant translocations are described. One, in whom cytogenetic remission was not achieved, had evidence of translocation of c-abl to chromosome 22, rearrangement of minor breakpoint cluster region (mBCR) and expression of hybrid bcr/abl transcripts. In the other case, no gene rearrangement was found and complete remission was achieved. Variant Ph translocations in childhood ALL are heterogeneous at the molecular level. Molecular studies coupled with observations of clinical outcome are needed in larger numbers of such children to determine whether poor clinical response correlates with bcr/abl involvement and to allow planning of appropriate therapeutic strategies.

UI MeSH Term Description Entries
D008297 Male Males
D010677 Philadelphia Chromosome An aberrant form of human CHROMOSOME 22 characterized by translocation of the distal end of chromosome 9 from 9q34, to the long arm of chromosome 22 at 22q11. It is present in the bone marrow cells of 80 to 90 per cent of patients with chronic myelocytic leukemia (LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE). Ph1 Chromosome,Ph 1 Chromosome,1 Chromosomes, Ph,Chromosome, Ph 1,Chromosome, Ph1,Chromosome, Philadelphia,Chromosomes, Ph 1,Chromosomes, Ph1,Ph 1 Chromosomes,Ph1 Chromosomes
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002889 Chromosomes, Human, Pair 2 A specific pair of human chromosomes in group A (CHROMOSOMES, HUMAN, 1-3) of the human chromosome classification. Chromosome 2
D002892 Chromosomes, Human, Pair 22 A specific pair of GROUP G CHROMOSOMES of the human chromosome classification. Chromosome 22
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014178 Translocation, Genetic A type of chromosome aberration characterized by CHROMOSOME BREAKAGE and transfer of the broken-off portion to another location, often to a different chromosome. Chromosomal Translocation,Translocation, Chromosomal,Chromosomal Translocations,Genetic Translocation,Genetic Translocations,Translocations, Chromosomal,Translocations, Genetic
D016044 Fusion Proteins, bcr-abl Translation products of a fusion gene derived from CHROMOSOMAL TRANSLOCATION of C-ABL GENES to the genetic locus of the breakpoint cluster region gene on chromosome 22. Several different variants of the bcr-abl fusion proteins occur depending upon the precise location of the chromosomal breakpoint. These variants can be associated with distinct subtypes of leukemias such as PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; and NEUTROPHILIC LEUKEMIA, CHRONIC. Oncogene Protein p190(bcr-abl),Oncogene Protein p210(bcr-abl),bcr-abl Fusion Protein,bcr-abl Fusion Proteins,Bcr-Abl Tyrosine Kinase,Oncogene Protein p185(bcr-abl),Oncogene Protein p230(bcr-abl),p185(bcr-abl) Fusion Proteins,p190(bcr-abl) Fusion Proteins,p210(bcr-abl) Fusion Proteins,p230(bcr-abl) Fusion Proteins,Bcr Abl Tyrosine Kinase,Fusion Protein, bcr-abl,Fusion Proteins, bcr abl,Kinase, Bcr-Abl Tyrosine,Protein, bcr-abl Fusion,Tyrosine Kinase, Bcr-Abl,bcr abl Fusion Protein,bcr abl Fusion Proteins

Related Publications

J A Latham, and N Bown, and G Cain, and P Middleton, and J Kernahan, and K Windebank, and M M Reid
August 2005, British journal of haematology,
J A Latham, and N Bown, and G Cain, and P Middleton, and J Kernahan, and K Windebank, and M M Reid
October 2018, British journal of haematology,
J A Latham, and N Bown, and G Cain, and P Middleton, and J Kernahan, and K Windebank, and M M Reid
December 1984, Journal of clinical pathology,
J A Latham, and N Bown, and G Cain, and P Middleton, and J Kernahan, and K Windebank, and M M Reid
May 2003, British journal of haematology,
J A Latham, and N Bown, and G Cain, and P Middleton, and J Kernahan, and K Windebank, and M M Reid
October 1987, Cytotechnology,
J A Latham, and N Bown, and G Cain, and P Middleton, and J Kernahan, and K Windebank, and M M Reid
January 1985, Cancer genetics and cytogenetics,
J A Latham, and N Bown, and G Cain, and P Middleton, and J Kernahan, and K Windebank, and M M Reid
September 2012, The Lancet. Oncology,
J A Latham, and N Bown, and G Cain, and P Middleton, and J Kernahan, and K Windebank, and M M Reid
February 1988, Cancer research,
J A Latham, and N Bown, and G Cain, and P Middleton, and J Kernahan, and K Windebank, and M M Reid
July 1988, British journal of haematology,
J A Latham, and N Bown, and G Cain, and P Middleton, and J Kernahan, and K Windebank, and M M Reid
March 2002, Best practice & research. Clinical haematology,
Copied contents to your clipboard!